Home
ABBV
ABBV News

Latest AbbVie Inc. (ABBV) News on November 6, 2025

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Motley Fool

6 hours ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Former blockbuster Linzess grows label with paediatric IBS-C approval

Pharmaceutical Technology

7 hours ago

Former blockbuster Linzess grows label with paediatric IBS-C approval

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

PR Newswire

8 hours ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Lower interest rates could boost these stocks & sectors

Yahoo Finance Video

8 hours ago

Lower interest rates could boost these stocks & sectors

Jim Cramer Says “I Found the AbbVie Call Particularly Jarring”

Insider Monkey

16 hours ago

Jim Cramer Says “I Found the AbbVie Call Particularly Jarring”

AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here?

Barchart

19 hours ago

AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here?

Morningstar Research

a day ago

Analyst Report: Royalty Pharma plc

MT Newswires

a day ago

AbbVie, Ironwood Win FDA Approval for Linzess to Treat Children With Irritable Bowel Syndrome With Constipation

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

Business Wire

a day ago

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

PR Newswire

a day ago

Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

3 Stocks Estimated To Be Trading Below Fair Value In November 2025

Simply Wall St.

2 days ago

3 Stocks Estimated To Be Trading Below Fair Value In November 2025

Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain Shifts - Global Forecast to 2034

GlobeNewswire

2 days ago

Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain Shifts - Global Forecast to 2034

MT Newswires

2 days ago

Bernstein Adjusts Price Target on AbbVie to $225 From $203, Maintains Market Perform Rating

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More

24/7 Wall St.

2 days ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More

3 Stocks Estimated To Be Trading Up To 25.8% Below Intrinsic Value

Simply Wall St.

2 days ago

3 Stocks Estimated To Be Trading Up To 25.8% Below Intrinsic Value

2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon

Motley Fool

2 days ago

2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon

BioSpace Announces 2026 Best Places to Work in Life Sciences Winners

PR Newswire

2 days ago

BioSpace Announces 2026 Best Places to Work in Life Sciences Winners

Do Wall Street Analysts Like AbbVie Stock?

Barchart

3 days ago

Do Wall Street Analysts Like AbbVie Stock?

MT Newswires

3 days ago

Rothschild & Co Redburn Adjusts AbbVie Price Target to $258 From $251

Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio

Insider Monkey

3 days ago

Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio

MT Newswires

3 days ago

Goldman Sachs Adjusts Price Target on AbbVie to $223 From $218

Analyst on AbbVie (ABBV): ‘Stay Long’

Insider Monkey

3 days ago

Analyst on AbbVie (ABBV): ‘Stay Long’

MT Newswires

3 days ago

Morgan Stanley Raises Price Target on AbbVie to $261 From $255, Keeps Overweight Rating

My Favorite Dividend King to Buy in November

Motley Fool

3 days ago

My Favorite Dividend King to Buy in November

MT Newswires

3 days ago

Raymond James Adjusts Price Target on AbbVie to $256 From $250, Maintains Outperform Rating

MT Newswires

3 days ago

JPMorgan Adjusts Price Target on AbbVie to $260 From $250, Maintains Overweight Rating

MT Newswires

3 days ago

BNP Paribas Exane Adjusts Price Target on AbbVie to $203 From $197, Maintains Neutral Rating

2 Magnificent Dividend Stocks to Buy and Hold Forever

Motley Fool

4 days ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

Why AbbVie Stock Flopped on Friday

Motley Fool

5 days ago

Why AbbVie Stock Flopped on Friday

AbbVie (ABBV) Margin Compression Reinforces Investor Caution After $14.5 Billion One-Off Loss

Simply Wall St.

6 days ago

AbbVie (ABBV) Margin Compression Reinforces Investor Caution After $14.5 Billion One-Off Loss

AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%

Investor's Business Daily

6 days ago

AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%

MT Newswires

6 days ago

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading

AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...

GuruFocus.com

6 days ago

AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...

AbbVie raises full-year forecast, Newell Brands stock plunges

Yahoo Finance Video

6 days ago

AbbVie raises full-year forecast, Newell Brands stock plunges

MT Newswires

6 days ago

Citigroup Cuts AbbVie's Price Target to $235 From $240

AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised

Zacks

6 days ago

AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised

MT Newswires

6 days ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

AbbVie Lifts Profit Outlook as Sales Rise

The Wall Street Journal

6 days ago

AbbVie Lifts Profit Outlook as Sales Rise

Investing.com

6 days ago

AbbVie lifts full-year profit outlook amid strong psoriasis drug demand

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

Barrons.com

6 days ago

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates

StockStory

6 days ago

AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates

MT Newswires

6 days ago

AbbVie Q3 Adjusted Earnings Fall, Revenue Rises; 2025 Adjusted EPS Guidance Lifted

Associated Press Finance

6 days ago

AbbVie: Q3 Earnings Snapshot

Exxon & Chevron earnings, Fed, YouTube-Disney: What to Watch

Yahoo Finance Video

7 days ago

Exxon & Chevron earnings, Fed, YouTube-Disney: What to Watch

AbbVie posts another win for Rinvoq in Phase III vitiligo trials

Clinical Trials Arena

7 days ago

AbbVie posts another win for Rinvoq in Phase III vitiligo trials

ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

CNW Group

7 days ago

ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

Amazon, Apple Earnings, ECB Rate Decision: Still to Come This Week

The Wall Street Journal

7 days ago

Amazon, Apple Earnings, ECB Rate Decision: Still to Come This Week

AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

StockStory

8 days ago

AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

Assessing AbbVie’s Value After 25.5% Rally and Oncology Growth Moves in 2025

Simply Wall St.

8 days ago

Assessing AbbVie’s Value After 25.5% Rally and Oncology Growth Moves in 2025

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

PR Newswire

8 days ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Trump Administration Eases Approval Process for Biosimilar Drugs

Barrons.com

8 days ago

Trump Administration Eases Approval Process for Biosimilar Drugs

Assessing AbbVie (ABBV) Valuation as Shares Approach Recent Highs and Outpace Sector Returns

Simply Wall St.

8 days ago

Assessing AbbVie (ABBV) Valuation as Shares Approach Recent Highs and Outpace Sector Returns

MT Newswires

8 days ago

AbbVie Says Upadacitinib Meets Endpoints in Replicate Phase 3 Vitiligo Studies

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

PR Newswire

8 days ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

With 74% institutional ownership, AbbVie Inc. (NYSE:ABBV) is a favorite amongst the big guns

Simply Wall St.

8 days ago

With 74% institutional ownership, AbbVie Inc. (NYSE:ABBV) is a favorite amongst the big guns

Jim Cramer Says “I Think Meta Has a Terrific Quarter”

Insider Monkey

9 days ago

Jim Cramer Says “I Think Meta Has a Terrific Quarter”

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Zacks

9 days ago

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Zacks

9 days ago

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?

Zacks

9 days ago

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?

Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?

Motley Fool

9 days ago

Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?

1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges

StockStory

10 days ago

1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

Zacks

10 days ago

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

Argus Research

10 days ago

Technical Assessment: Bullish in the Intermediate-Term

Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade

Motley Fool

11 days ago

Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts

Simply Wall St.

12 days ago

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts

AI Chatbots Were Told to Trade Crypto. The Returns Were Ugly.

Barrons.com

13 days ago

AI Chatbots Were Told to Trade Crypto. The Returns Were Ugly.

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch

Yahoo Finance Video

13 days ago

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch

Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for

Zacks

13 days ago

Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?

Zacks

13 days ago

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?

MT Newswires

14 days ago

Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating

United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio

GlobeNewswire

14 days ago

United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Zacks

15 days ago

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation

Insider Monkey

15 days ago

Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation

Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative

Simply Wall St.

15 days ago

Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative

AbbVie Inc. (ABBV): A Bull Case Theory

Insider Monkey

15 days ago

AbbVie Inc. (ABBV): A Bull Case Theory

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

Zacks

15 days ago

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Zacks

15 days ago

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

This 3 Stocks Portfolio Provides Monthly Income

Zacks

16 days ago

This 3 Stocks Portfolio Provides Monthly Income

Top Stock Reports for Apple, Meta Platforms & JPMorgan

Zacks

16 days ago

Top Stock Reports for Apple, Meta Platforms & JPMorgan

AbbVie's Rinvoq Beats Humira in Key Arthritis Trial

GuruFocus.com

16 days ago

AbbVie's Rinvoq Beats Humira in Key Arthritis Trial

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

PR Newswire

16 days ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates

Simply Wall St.

16 days ago

Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates

MT Newswires

16 days ago

BMO Capital Adjusts Price Target on AbbVie to $258 From $240, Maintains Outperform Rating

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

Zacks

17 days ago

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

MT Newswires

17 days ago

AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial

AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin

TipRanks

19 days ago

AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin

MT Newswires

20 days ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires

20 days ago

Novo Nordisk Hires AbbVie Executive as Trump Mounts Pricing Pressure

MT Newswires

20 days ago

AbbVie Closes Bretisilocin Acquisition

MT Newswires

20 days ago

Raymond James Adjusts Price Target on AbbVie to $250 From $236, Maintains Outperform Rating

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

PR Newswire

20 days ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

3 Stocks Trading At Discounts Of Up To 48.8% Below Estimated Intrinsic Value

Simply Wall St.

21 days ago

3 Stocks Trading At Discounts Of Up To 48.8% Below Estimated Intrinsic Value

Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery

PR Newswire

21 days ago

Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery

October 2025 Value Picks: 3 Stocks That May Offer Attractive Valuations

Simply Wall St.

21 days ago

October 2025 Value Picks: 3 Stocks That May Offer Attractive Valuations

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Motley Fool

21 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)

Insider Monkey

22 days ago

Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)

AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks

22 days ago

AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know

Investing.com

22 days ago

Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Business Wire

22 days ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Argus Research

22 days ago

Technical Assessment: Bullish in the Intermediate-Term

Share on Social Networks: